Showing results (651-660 of 658) with videos related to

Sort By:
Pageof 66
You have reached the last page of results.This site can display upto 658 results.
American Journal of Respiratory and Critical Care Medicine|March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del AlleleEdith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.
The European Respiratory Journal|November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension studyCori L Daines, Elizabeth Tullis, Stefano Costa, et al.
American Journal of Medical Genetics. Part A|February 1, 2017
A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmusP Dunn, G P Prigatano, S Szelinger, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled StudyMarcus A Mall, Rossa Brugha, Silvia Gartner, et al.
Microbiome|April 3, 2020
Lung function and microbiota diversity in cystic fibrosisLeah Cuthbertson, Alan W Walker, Anna E Oliver, et al.
The Lancet. Haematology|November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm studyMazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
International Journal of Molecular Sciences|July 24, 2021
The Critical Importance of Molecular Biomarkers and Imaging in the Study of Electrohypersensitivity. A Scientific Consensus International ReportDominique Belpomme, George L Carlo, Philippe Irigaray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2024
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AMLBoglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, et al.
Pageof 66